Education
About Us
Working with TipRanks
Follow Us
BioLargo Inc (BLGO)
OTHER OTC:BLGO
Top Page
BioLargo
(OTC:BLGO)
55Neutral
BioLargo (BLGO) vs. S&P 500 (SPY)
Market Cap
$72.31M
Dividend YieldN/A
Average Volume (3M)215.90K
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue Growth45.40%
EPS Growth34.43%
CountryUS
Employees31
SectorBasic Materials
Sector Strength58
IndustryChemicals
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding301,303,130
10 Day Avg. Volume185,834
30 Day Avg. Volume215,897
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.72
Price to Cash Flow (P/CF)-13.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BioLargo Business Overview & Revenue Model
Company DescriptionBioLargo, Inc. (BLGO) is a technology-driven company operating in the environmental engineering and life sciences sectors. It focuses on developing and commercializing innovative technologies aimed at solving significant environmental challenges, such as water contamination and air quality issues. The company's core products and services include advanced water treatment solutions, odor and volatile organic compound (VOC) control systems, and infection control products.
How the Company Makes MoneyBioLargo makes money through the sale and licensing of its proprietary technologies and products. Key revenue streams include direct sales of their water treatment systems and odor control products to industrial and municipal clients, as well as licensing agreements for the use of their patented technologies. The company also generates income through strategic partnerships with other organizations that leverage BioLargo's innovations to enhance their own product offerings. Additionally, consulting services provided by BioLargo Engineering, Science & Technologies (BLEST) contribute to the company's revenue by offering specialized expertise in environmental engineering projects.
BioLargo Financial Statement Overview
Summary
BioLargo shows promising revenue growth but continues to face significant challenges in achieving profitability and positive cash flow. The balance sheet is strengthened by low leverage but hampered by negative profitability. The company's focus should be on improving operational efficiency and profitability to enhance cash flow and shareholder value.Income Statement
BioLargo has shown significant revenue growth over the past few years, with TTM revenues reaching $18.5 million, up from $12.2 million in the previous year. Despite this growth, the company remains unprofitable, with negative EBIT, EBITDA, and net income margins. The TTM net profit margin stands at -11.45%, which suggests the company is struggling to convert revenue into profit.48
Neutral
Balance Sheet
The balance sheet reflects a stable equity position with stockholders' equity increasing to $8.6 million. The debt-to-equity ratio is relatively low at 0.17, indicating moderate leverage. However, equity ratio at 83.23% indicates a strong reliance on equity financing. While the company has managed to improve its equity base, the persistent negative net income impacts return on equity.55
Neutral
Cash Flow
Cash flow generation remains a challenge for BioLargo, with negative free cash flow and operating cash flow in the TTM. The operating cash flow to net income ratio is negative, reflecting inefficiencies in converting sales into actual cash. Although free cash flow improved slightly, it remains negative, suggesting ongoing cash burn and reliance on external financing.42
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 18.50M | 12.23M | 5.88M | 2.53M | 2.43M | 1.86M | Gross Profit |
| 8.19M | 6.15M | 2.86M | 1.10M | 1.23M | 916.00K | EBIT |
| -3.30M | -4.19M | -5.12M | -6.38M | -7.45M | -6.48M | EBITDA |
| -3.35M | -4.19M | -5.10M | -6.70M | -7.83M | -7.44M | Net Income Common Stockholders |
| -2.12M | -3.50M | -4.50M | -7.38M | -10.47M | -14.75M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 921.94K | 3.54M | 1.85M | 962.00K | 716.00K | 655.00K | Total Assets |
| 1.46M | 8.21M | 4.86M | 3.02M | 4.94M | 3.62M | Total Debt |
| 5.72M | 1.70M | 1.47M | 1.13M | 2.67M | 4.52M | Net Debt |
| 4.80M | -1.84M | -383.00K | 171.00K | 1.96M | 3.87M | Total Liabilities |
| 6.07M | 4.00M | 2.85M | 2.09M | 5.18M | 5.80M | Stockholders Equity |
| -5.20M | 6.84M | 4.88M | 4.65M | 3.86M | -2.15M |
| Cash Flow | Free Cash Flow | ||||
| -1.44M | -2.84M | -3.03M | -3.97M | -4.18M | -4.46M | Operating Cash Flow |
| -1.29M | -2.37M | -2.76M | -3.94M | -4.15M | -4.42M | Investing Cash Flow |
| -1.41M | -478.00K | -271.00K | -34.00K | -123.00K | -35.00K | Financing Cash Flow |
| 3.61M | 4.66M | 3.96M | 4.23M | 4.34M | 4.47M |
BioLargo Technical Analysis
Negative
0.24
Price Trends
0.26
Negative
0.24
Negative
0.24
Negative
Market Momentum
<0.01
Negative
49.97
Neutral
41.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Negative. The current price of 0.24 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.26, and below the 200-day MA of 0.24, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.97 is Neutral, neither overbought nor oversold. The STOCH value of 41.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLGO.
BioLargo Risk Analysis
BioLargo disclosed 44 risk factors in its most recent earnings report. BioLargo reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioLargo Peers Comparison
Overall Rating
UnderperformOutperform
Sector (47)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $1.42M | ― | 33.13% | ― | ― | ― | |
55 Neutral | $72.31M | ― | -30.61% | ― | 45.40% | 34.43% | |
52 Neutral | $92.16M | ― | 75.79% | ― | 10.19% | 44.46% | |
47 Neutral | $2.32B | -2.83 | -21.67% | 3.65% | 4.83% | -28.82% | |
45 Neutral | $26.21M | ― | -55.91% | ― | 49.65% | 16.68% | |
42 Neutral | $12.78B | ― | -94.89% | ― | ― | 80.00% | |
41 Neutral | $126.05M | ― | -38.46% | ― | -34.12% | -3803.38% |
* Basic Materials Sector Average
Performance Comparison
BLGO
BioLargo
0.24
-0.08
-25.00%
CDTI
CDTi Advanced Materials
0.40
-0.20
-33.33%
PESI
Perma-Fix
6.51
-5.07
-43.78%
CLIR
ClearSign Combustion
0.50
-0.49
-49.49%
SMMT
Summit Therapeutics
16.64
12.56
307.84%
OPTN
Optinose
9.05
-9.40
-50.95%
BioLargo Earnings Call Summary
Earnings Call Date: Mar 31, 2025 | % Change Since: -14.29% | Next Earnings Date: May 14, 2025
Earnings Call Sentiment Positive
BioLargo's earnings call presented a positive outlook, with significant revenue growth and advancements across its subsidiaries. However, challenges in specific projects and revenue fluctuations in key products indicate areas needing attention. Overall, the sentiment is optimistic with caution regarding operational hurdles.Highlights
Significant Revenue Growth
BioLargo achieved an overall sales and revenue increase of 45%, reaching nearly $18 million. The growth was driven by various subsidiaries, showcasing an accelerated growth path.
Impressive Subsidiary Performance
Odor-No-More saw a revenue increase of 36%, generating $5.9 million in operating income. The engineering division also experienced revenue growth of 183%.
Positive Balance Sheet Developments
BioLargo reported a strong balance sheet, maintaining $3.5 million in cash, increased accounts receivable due to business development, and reduced overall debt.
Pooph Product Success
The Pooph product line, with eight unique products and 15 SKUs, has been performing exceptionally well in retail, contributing significantly to revenue growth.
Clyra Medical Nearing Market Readiness
Clyra Medical is approaching the launch of its innovative product, with significant investments in manufacturing and a successful inspection confirming scale capability.
Lowlights
Pooph Revenue Fluctuations
Despite its success, Pooph product revenue experienced an ebb and flow, with a noted decrease in Q4 compared to Q3, potentially due to marketing spend adjustments.
Delayed AEC Projects
Projects related to the AEC technology, such as the New Jersey installation, have faced delays due to external factors like weather and construction timelines.
Garratt-Callahan Partnership Challenges
The partnership with Garratt-Callahan for minimum liquid discharge units has not yielded the expected results, with adoption challenges cited.
Battery Technology Validation Delays
Third-party validation for the Spartan cell battery technology has been slower than anticipated, with efforts ongoing to secure necessary validation.
Company Guidance
In the BioLargo Annual 2024 Earnings Results call, the company provided several key metrics that underscore its growth and future potential. The company reported a 45% increase in overall sales and revenue, reaching nearly $18 million. Specific subsidiaries also showed significant growth, with Odor-No-More's revenue increasing by 36%, contributing $5.9 million in operating income. The engineering division saw a 183% increase in third-party revenue, although it still operated at a loss of $1.45 million, down from $1.6 million the previous year. Clyra Medical Technologies, a subsidiary focused on medical products, was identified as the majority contributor to the net loss, which decreased to $4.3 million from $4.6 million. Moreover, the company highlighted substantial investments and partnerships, particularly in the battery and PFAS sectors, indicating a multibillion-dollar opportunity in battery technology and significant cost-saving potential in PFAS treatment. BioLargo also maintained a strong balance sheet with $3.5 million in cash and an increase in accounts receivable, reflecting its expanding business. The company aims to continue its upward trajectory with strategic partnerships and product innovations, setting the stage for potential exits and increased shareholder value.BioLargo Corporate Events
Other
BioLargo Presents at Webcast Investor Conference
Neutral
Mar 31, 2025
BioLargo, Inc. presented a slide presentation on March 31, 2025, at a webcast investor conference and plans to release a press statement on April 1, 2025. The company clarified that the information shared is not subject to certain securities liabilities and will not be incorporated into any SEC filings, emphasizing its discretion to update this information as deemed appropriate.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.